JP2001501957A - アミノチオフェンカルボキサミド - Google Patents
アミノチオフェンカルボキサミドInfo
- Publication number
- JP2001501957A JP2001501957A JP10517986A JP51798698A JP2001501957A JP 2001501957 A JP2001501957 A JP 2001501957A JP 10517986 A JP10517986 A JP 10517986A JP 51798698 A JP51798698 A JP 51798698A JP 2001501957 A JP2001501957 A JP 2001501957A
- Authority
- JP
- Japan
- Prior art keywords
- carbamoyl
- ylcarbamoyl
- formula
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.下記式(I)で示される化合物およびその生理学的に許容できる塩: 式中、 R1およびR2は、互いに独立して、それぞれH、A、OA、アルケニル、アルキニル 、CF3またはHalを表わし、基R1またはR2の一方は常にHでなく、 R1およびR2はまた一緒になって炭素原子数3〜5のアルキレンを表わし、 R3およびR4は、互いに独立して、それぞれH、A、OA、NO2、NH2またはHalを表 わし、 R3およびR4はまた一緒になって-O-CH2-CH2-、-O-CH2-O-または-O-CH2-CH2-O- を表わし、 AおよびA'は、互いに独立して、それぞれHまたは炭素原子数1〜6のアルキル を表わし、 R5は、-X-Yを表わし、 Xは、CO、CSまたはSO2を表わし、 Yは、非置換またはCOOH、COOA、CONH2、CONAA'、CONHA、CN、NHSO2A、N(SO2A)2 またはSO2Aにより一置換もしくは二置換されている飽和または不飽和5〜7員 同素環式または複素環式環を表わし、 HalはF、Cl、BrまたはIを表わし、および nは0、1、2または3を表わす。 2.(a)4-{3-[(ベンゾ[1,3]ジオキソル-5-イルメチル)カルバモイル]-4,5,6,7 -テトラヒドロベンゾ[b]チオフェン-2-イルカルバモイル}安息香酸; (b)4-[3-(ベンジルカルバモイル)-5-メチルチオフェン-2-イルカルバモイル ]安息香酸; (c)4-{3-[(ベンゾ[1,3]ジオキソル-5-イルメチル)カルバモイル]-5-メチル チオフェン-2-イルカルバモイル}安息香酸; (d)4-{3-[(ベンゾ[1,3]ジオキソル-5-イルメチル)カルバモイル]-5-メチル チオフェン-2-イルカルバモイル}シクロヘキサンカルボン酸; (e)4-{3-[(ベンゾ[1,3]ジオキソル-5-イルメチル)カルバモイル]-4,5,6,7- テトラヒドロベンゾ[b]チオフェン-2-イルカルバモイル}安息香酸; (f)4-{3-[(3-クロロ-4-メトキシベンジル)カルバモイル]-4,5,6,7-テトラヒ ドロベンゾ[b]チオフェン-2-イルカルバモイル}安息香酸; (g)4-{3-[(3-クロロ-4-メトキシベンジル)カルバモイル]-5-メチルチオフェ ン-2-イルカルバモイル}安息香酸; (h)4-{3-[(3-クロロ-4-メトキシベンジル)カルバモイル]-5-エチルチオフェ ン-2-イルカルバモイル}安息香酸; (i)4-{3-[(3-クロロ-4-メトキシベンジル)カルバモイル]-4,5,6,7-テトラヒ ドロベンゾ[b]チオフェン-2-イルカルバモイル}シクロヘキサンカルボン酸; (k)4-{3-[(3-クロロ-4-メトキシベンジル)カルバモイル]-5-メチルチオフェ ン-2-イルカルバモイル}シクロヘキサンカルボン酸 である請求項1に記載の式(I)で示される化合物およびその生理学的に許容で きる塩。 3.請求項1の式(I)で示される化合物およびその塩の調製方法であって: (a)下記式(II)で示される化合物 (式中、R1、R2、R3、R4およびは前記意味を有する。) を下記式(III)で示される化合物 L-R5 (III) (式中、R5は前記意味を有し、LはCl、Br、I、OHまたは、エステル化により反応 性になるOH基を表わす。) と反応させる、 または (b)下記式(IV)で示される化合物 (式中、R1、R2、R5およびAおよびは前記意味を有し、LはCl、Br、I、OHまたは 、エステル化により反応性になるOH基を表わす。) を下記式(V)で示される化合物 (式中、R4、R5およびnは前記意味を有する。) と反応させる、 または (c)式(I)で示される化合物中において、基R3、R4および/またはR5をエステル の加水分解またはニトロ基の還元により別の基R3、R4および/またはR5に転化す る、ならびに/もしくは、式(I)で示される酸を塩基での処理によりその塩の 一つに転化する ことを特徴とする方法。 4.薬剤組成物の調製方法であって、請求項1に記載の式(I)で示される化 合物および/またはその生理学的に許容できる塩の一つを、少なくとも一つの固 体、液体または半液体ビヒクルまたは賦形剤と共に適当な投与形状にすることを 特徴とする方法。 5.請求項1の式(I)で示される少なくとも一つの化合物および/またはそ の薬理学的に許容できる塩の一つを含むことを特徴とする薬剤組成物。 6.心臓血管系の病気の治療のため、および性交能障害の治療のための請求項 1の式(I)で示される化合物およびその生理学的に許容できる塩。 7.ホスホジエステラーゼV阻害剤としての、請求項1の式(I)で示される化 合物およびその生理学的に許容できる塩の薬剤。 8.薬剤の調製のための、請求項1の式(I)で示される化合物および/また はその生理学的に許容できる塩の使用。 9.病気の治療における、請求項1の式(I)で示される化合物および/また はその生理学的に許容できる塩の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19642451.8 | 1996-10-15 | ||
DE19642451A DE19642451A1 (de) | 1996-10-15 | 1996-10-15 | Aminothiophencarbonsäureamide |
PCT/EP1997/005531 WO1998016521A1 (de) | 1996-10-15 | 1997-10-08 | Aminothiophencarbonsäureamide und ihre verwendung als phosphodiesterase inhibitoren |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001501957A true JP2001501957A (ja) | 2001-02-13 |
JP4243352B2 JP4243352B2 (ja) | 2009-03-25 |
Family
ID=7808775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51798698A Expired - Fee Related JP4243352B2 (ja) | 1996-10-15 | 1997-10-08 | アミノチオフェンカルボキサミド |
Country Status (26)
Country | Link |
---|---|
US (1) | US6143777A (ja) |
EP (1) | EP0934301B1 (ja) |
JP (1) | JP4243352B2 (ja) |
KR (1) | KR100479811B1 (ja) |
CN (1) | CN1110493C (ja) |
AR (1) | AR009985A1 (ja) |
AT (1) | ATE202347T1 (ja) |
AU (1) | AU725741B2 (ja) |
BR (1) | BR9712321A (ja) |
CA (1) | CA2268886C (ja) |
CZ (1) | CZ297253B6 (ja) |
DE (2) | DE19642451A1 (ja) |
DK (1) | DK0934301T3 (ja) |
ES (1) | ES2159851T3 (ja) |
GR (1) | GR3036341T3 (ja) |
HK (1) | HK1020724A1 (ja) |
HU (1) | HUP9904703A3 (ja) |
NO (1) | NO991776L (ja) |
PL (1) | PL192109B1 (ja) |
PT (1) | PT934301E (ja) |
RU (1) | RU2184731C2 (ja) |
SI (1) | SI0934301T1 (ja) |
SK (1) | SK283807B6 (ja) |
TW (1) | TW438791B (ja) |
WO (1) | WO1998016521A1 (ja) |
ZA (1) | ZA979199B (ja) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6727258B2 (en) * | 1997-10-29 | 2004-04-27 | King Pharmaceutical Research & Development, Inc. | Allosteric adenosine receptor modulators |
US6410584B1 (en) | 1998-01-14 | 2002-06-25 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells with indole derivatives |
AU4514799A (en) * | 1998-06-19 | 2000-01-10 | Syngenta Participations Ag | Process for preparation of pyrimidinone derivatives |
US6200771B1 (en) | 1998-10-15 | 2001-03-13 | Cell Pathways, Inc. | Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia |
US6133271A (en) * | 1998-11-19 | 2000-10-17 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives |
US6187779B1 (en) | 1998-11-20 | 2001-02-13 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives |
US6369092B1 (en) | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
US6077842A (en) * | 1998-11-24 | 2000-06-20 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives |
US6034099A (en) * | 1998-11-24 | 2000-03-07 | Cell Pathways, Inc. | Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones |
US6486155B1 (en) | 1998-11-24 | 2002-11-26 | Cell Pathways Inc | Method of inhibiting neoplastic cells with isoquinoline derivatives |
US6020379A (en) * | 1999-02-19 | 2000-02-01 | Cell Pathways, Inc. | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
JP2005504806A (ja) * | 2001-09-21 | 2005-02-17 | スミスクライン・ビーチャム・コーポレイション | 化合物 |
JP2005506334A (ja) * | 2001-10-04 | 2005-03-03 | スミスクライン・ビーチャム・コーポレイション | NF−κB阻害剤 |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7196207B2 (en) * | 2002-07-24 | 2007-03-27 | Mitsui Chemicals, Inc. | Method for producing 2-alkyl-3-aminothiophene derivative |
US7179836B2 (en) * | 2002-09-20 | 2007-02-20 | Smithkline Beecham Corporation | Chemical compounds |
FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
CA2620333A1 (en) | 2005-08-26 | 2007-03-01 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
AU2006304787A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP2021000A2 (en) | 2006-05-09 | 2009-02-11 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
MY157445A (en) * | 2008-08-27 | 2016-06-15 | Calcimedica Inc | Compounds that modulate intracellular calcium. |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US20150119399A1 (en) | 2012-01-10 | 2015-04-30 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
RU2503671C1 (ru) * | 2012-07-31 | 2014-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | (Z)-2-[(3-КАРБАМОИЛ-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-(4-R-ФЕНИЛ)-4-ОКСОБУТ-2-ЕНОВЫЕ КИСЛОТЫ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ |
RU2501795C1 (ru) * | 2012-10-01 | 2013-12-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Пермский государственный национальный исследовательский университет" | N-R-АМИДЫ (Z)-2[(3-ЭТОКСИКАРБОНИЛ)-4,5,6,7-ТЕТРАГИДРОБЕНЗО[b]ТИЕН-2-ИЛ)АМИНО]-4-ФЕНИЛ-4-ОКСОБУТ-2-ЕНОВЫХ КИСЛОТ, ОБЛАДАЮЩИЕ АНАЛЬГЕТИЧЕСКОЙ АКТИВНОСТЬЮ |
EP3157520B1 (en) | 2014-06-23 | 2019-09-04 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
RU2722176C1 (ru) * | 2019-09-06 | 2020-05-28 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | (z)-2((4-r1-5-r2-3-(этоксикарбонил)тиофен-2-ил)амино)-4-оксо-4-r3-бут-2-еновые кислоты, обладающие противомикробной активностью |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5075310A (en) * | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
US5753692A (en) * | 1992-02-19 | 1998-05-19 | Industrial Technology Research Institute | Medicinal thiophene compounds |
US5356926A (en) * | 1992-02-24 | 1994-10-18 | Warner-Lambert Company | 3-alkyloxy-, aryloxy-, or arylalkyloxy-benzo [β]thiophene-2-carboxamides as inhibitors of cell adhesion |
DE4230755A1 (de) * | 1992-09-14 | 1994-03-17 | Schering Ag | Verwendung von PDE-Inhibitoren bei der Behandlung von Nieren- und Ureter-Erkrankungen |
DK148292D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Forbindelser |
GB9309324D0 (en) * | 1993-05-06 | 1993-06-16 | Bayer Ag | Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives |
DE4317076A1 (de) * | 1993-05-21 | 1994-11-24 | Bayer Ag | Benzthiophencarbonsäureamid-S-oxide |
ATE175667T1 (de) * | 1994-05-31 | 1999-01-15 | Bayer Ag | Aminobenzofuryl- und -thienylderivate |
US5863936A (en) * | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
WO1998015545A1 (en) * | 1996-10-08 | 1998-04-16 | Eli Lilly And Company | New serotonin 5-ht1f agonists |
US5783597A (en) * | 1997-03-04 | 1998-07-21 | Ortho Pharmaceutical Corporation | 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use |
-
1996
- 1996-10-15 DE DE19642451A patent/DE19642451A1/de not_active Withdrawn
-
1997
- 1997-10-06 TW TW086114589A patent/TW438791B/zh active
- 1997-10-08 DK DK97912140T patent/DK0934301T3/da active
- 1997-10-08 WO PCT/EP1997/005531 patent/WO1998016521A1/de active IP Right Grant
- 1997-10-08 CA CA002268886A patent/CA2268886C/en not_active Expired - Fee Related
- 1997-10-08 KR KR10-1999-7003246A patent/KR100479811B1/ko not_active IP Right Cessation
- 1997-10-08 SK SK432-99A patent/SK283807B6/sk unknown
- 1997-10-08 DE DE59703869T patent/DE59703869D1/de not_active Expired - Lifetime
- 1997-10-08 PL PL332802A patent/PL192109B1/pl unknown
- 1997-10-08 EP EP97912140A patent/EP0934301B1/de not_active Expired - Lifetime
- 1997-10-08 CZ CZ0124099A patent/CZ297253B6/cs not_active IP Right Cessation
- 1997-10-08 CN CN97198839A patent/CN1110493C/zh not_active Expired - Fee Related
- 1997-10-08 SI SI9730192T patent/SI0934301T1/xx unknown
- 1997-10-08 AT AT97912140T patent/ATE202347T1/de not_active IP Right Cessation
- 1997-10-08 AU AU49451/97A patent/AU725741B2/en not_active Ceased
- 1997-10-08 ES ES97912140T patent/ES2159851T3/es not_active Expired - Lifetime
- 1997-10-08 HU HU9904703A patent/HUP9904703A3/hu unknown
- 1997-10-08 US US09/284,501 patent/US6143777A/en not_active Expired - Fee Related
- 1997-10-08 JP JP51798698A patent/JP4243352B2/ja not_active Expired - Fee Related
- 1997-10-08 PT PT97912140T patent/PT934301E/pt unknown
- 1997-10-08 RU RU99109576/04A patent/RU2184731C2/ru not_active IP Right Cessation
- 1997-10-08 BR BR9712321-8A patent/BR9712321A/pt not_active Application Discontinuation
- 1997-10-14 ZA ZA9709199A patent/ZA979199B/xx unknown
- 1997-10-15 AR ARP970104736A patent/AR009985A1/es not_active Application Discontinuation
-
1999
- 1999-04-14 NO NO991776A patent/NO991776L/no not_active Application Discontinuation
- 1999-11-04 HK HK99105058A patent/HK1020724A1/xx not_active IP Right Cessation
-
2001
- 2001-08-07 GR GR20010401193T patent/GR3036341T3/el not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001501957A (ja) | アミノチオフェンカルボキサミド | |
US5948777A (en) | Cannabinoid receptor agonists | |
JP4740115B2 (ja) | 置換ピラゾール | |
US20040002524A1 (en) | Benzimidazole compounds and their use as estrogen agonists/antagonists | |
JP2001526220A (ja) | 置換複素環式尿素を用いたrafキナーゼの阻害 | |
JPH0236163A (ja) | 新規なヒドロキサメート誘導体 | |
HU201300B (en) | Process for production of derivatives of aryl and medical compositions containing them as active substance | |
JP2005533858A (ja) | 化合物 | |
WO2006018662A2 (en) | Aryl urea derivatives for treating obesity | |
CN101489551A (zh) | 氨基吲唑脲衍生物 | |
JP2004521915A (ja) | Tgf過剰発現に対するピラゾール誘導体 | |
US6531473B2 (en) | Method of treatment using arylalkylpyridazinones | |
JP2001525325A (ja) | チエノピリミジン類 | |
AU2004228121B2 (en) | 1,3,4-substituted pyrazoles for use as 5-HT receptor antagonists in the treatment of psychoses and neurological disorders | |
CN110357789A (zh) | 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途 | |
JP2011513214A (ja) | 11β−ヒドロキシステロイドデヒドロゲナーゼ阻害剤 | |
JP2002513026A (ja) | ホスホジエステラーゼv阻害作用を有する凝縮チエノピリミジン類 | |
KR20050119195A (ko) | 피라졸 화합물 | |
KR20050119192A (ko) | 치환된 피라졸 화합물 | |
JPH0583551B2 (ja) | ||
JP2006527706A (ja) | セロトニン再取り込み阻害剤としてのインドール誘導体 | |
JP2002541095A (ja) | アリールアルカノイルピリダジンの使用 | |
JP4198755B6 (ja) | アリールアルカノイルピリダジン誘導体 | |
JP4198755B2 (ja) | アリールアルカノイルピリダジン誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041004 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20041004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080715 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081014 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081202 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090105 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120109 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |